Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study

Unknown, Bernies van der Hiel, John B.A.G. Haanen, Marcel P.M. Stokkel, Daniel S. Peeper, Connie R. Jimenez, Jos H. Beijnen, Bart A. van de Wiel, Ronald Boellaard, Alfons J.M. van den Eertwegh

Open source

DOI: 10.1186/s12885-017-3626-5
Published: 2017-09-15
Container: BMC Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-017-3626-5,
  title = {Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study},
  author = {Unknown and Bernies van der Hiel and John B.A.G. Haanen and Marcel P.M. Stokkel and Daniel S. Peeper and Connie R. Jimenez and Jos H. Beijnen and Bart A. van de Wiel and Ronald Boellaard and Alfons J.M. van den Eertwegh},
  year = {2017},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-017-3626-5},
  url = {https://doi.org/10.1186/s12885-017-3626-5}
}

RIS

TY  - JOUR
TI  - Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study
AU  - Unknown
AU  - Bernies van der Hiel
AU  - John B.A.G. Haanen
AU  - Marcel P.M. Stokkel
AU  - Daniel S. Peeper
AU  - Connie R. Jimenez
AU  - Jos H. Beijnen
AU  - Bart A. van de Wiel
AU  - Ronald Boellaard
AU  - Alfons J.M. van den Eertwegh
PY  - 2017
JO  - BMC Cancer
DO  - 10.1186/s12885-017-3626-5
UR  - https://doi.org/10.1186/s12885-017-3626-5
ER  -

APA

Unknown, Hiel, B. V. D., Haanen, J. B., Stokkel, M. P., Peeper, D. S., Jimenez, C. R., Beijnen, J. H., Wiel, B. A. V. D., Boellaard, R., & Eertwegh, A. J. V. D. (2017). Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer. https://doi.org/10.1186/s12885-017-3626-5

Source records

crossref · retrieved 2026-09-25T22:28:28.827Z